Brief: Endonovo’S Sofpulse® Nears Final Stages To Receive Taiwan FDA License To Distribute In Taiwan
23/03/2023 13:16
March 23 (Reuters) - Endonovo Therapeutics Inc
ENDV.PK :
* ENDONOVO’S SOFPULSE® NEARS FINAL STAGES TO RECEIVE TAIWAN
FDA
LICENSE TO DISTRIBUTE IN TAIWAN
Source text for Eikon: ID:nGNXSzkfv
Further company coverage: ENDV.PK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Endonovo Therapeutics
See all newsBrief: Endonovo To Sell SofPulse Brand Business And IP To SofPulse Inc For A Minimum Of $50 Million
Brief: Endonovo’S Sofpulse® Nears Final Stages To Receive Taiwan FDA License To Distribute In Taiwan
Brief: Endonovo Therapeutics Inc - Sofpulse, Inc. Will Operate Independently After Planned Spin-Off
Brief: Endonovo Therapeutics Details Plan To Spin Off Medical Device Division As A Listed Public Company
Brief: Endonovo Announces Plan To Explore Strategic Alternatives For Its Sofpulse Medical Device Assets